Charles L. Vogel

23.1k total citations · 6 hit papers
163 papers, 16.8k citations indexed

About

Charles L. Vogel is a scholar working on Oncology, Cancer Research and Pulmonary and Respiratory Medicine. According to data from OpenAlex, Charles L. Vogel has authored 163 papers receiving a total of 16.8k indexed citations (citations by other indexed papers that have themselves been cited), including 112 papers in Oncology, 48 papers in Cancer Research and 34 papers in Pulmonary and Respiratory Medicine. Recurrent topics in Charles L. Vogel's work include Cancer Treatment and Pharmacology (67 papers), HER2/EGFR in Cancer Research (52 papers) and Breast Cancer Treatment Studies (45 papers). Charles L. Vogel is often cited by papers focused on Cancer Treatment and Pharmacology (67 papers), HER2/EGFR in Cancer Research (52 papers) and Breast Cancer Treatment Studies (45 papers). Charles L. Vogel collaborates with scholars based in United States, Uganda and United Kingdom. Charles L. Vogel's co-authors include Melody Cobleigh, Dennis J. Slamon, Louis Fehrenbacher, Debu Tripathy, Steven Shak, Janet Wolter, Nicholas J. Robert, Virginia Paton, Suzy Scholl and Vincent T. DeVita and has published in prestigious journals such as Journal of Clinical Oncology, Blood and Annals of Internal Medicine.

In The Last Decade

Charles L. Vogel

160 papers receiving 16.0k citations

Hit Papers

Efficacy and Safety of Tr... 1970 2026 1988 2007 2002 1999 2002 1970 1999 500 1000 1.5k 2.0k
What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

  1. Efficacy and Safety of Trastuzumab as a Single Agent in First-Line Treatment of HER2-Overexpressing Metastatic Breast Cancer
    2002 2.3k citations Charles L. Vogel Journal of Clinical Oncology profile →
  2. Multinational Study of the Efficacy and Safety of Humanized Anti-HER2 Monoclonal Antibody in Women Who Have HER2-Overexpressing Metastatic Breast Cancer That Has Progressed After Chemotherapy for Metastatic Disease
    1999 2.2k citations Melody Cobleigh, Charles L. Vogel et al. Journal of Clinical Oncology profile →
  3. Efficacy and Safety of Trastuzumab as a Single Agent in First-Line Treatment of HER2-Overexpressing Metastatic Breast Cancer
    2002 1.5k citations Charles L. Vogel, Melody Cobleigh et al. Journal of Clinical Oncology profile →
  4. THE SPECTRUM OF THE DISEASE IN 98 PATIENTS
    1970 798 citations Charles L. Vogel et al. profile →
  5. Multicenter Phase II Study of Capecitabine in Paclitaxel-Refractory Metastatic Breast Cancer
    1999 655 citations Patricia LoRusso, Charles L. Vogel et al. Journal of Clinical Oncology profile →
  6. Phase II Study of the Antibody Drug Conjugate Trastuzumab-DM1 for the Treatment of Human Epidermal Growth Factor Receptor 2 (HER2) –Positive Breast Cancer After Prior HER2-Directed Therapy
    2010 568 citations Howard A. Burris, Hope S. Rugo et al. Journal of Clinical Oncology profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Charles L. Vogel United States 56 11.4k 4.4k 3.6k 3.6k 2.7k 163 16.8k
M. Elizabeth Hammond United States 28 6.7k 0.6× 2.4k 0.5× 4.0k 1.1× 2.2k 0.6× 2.0k 0.8× 60 11.5k
Michael J. Mihatsch Switzerland 67 8.1k 0.7× 1.6k 0.4× 2.9k 0.8× 7.4k 2.1× 4.9k 1.8× 319 20.8k
Rebecca Gelman United States 63 6.8k 0.6× 1.8k 0.4× 6.5k 1.8× 2.4k 0.7× 2.6k 1.0× 223 16.1k
Sabino De Placido Italy 64 7.8k 0.7× 1.6k 0.4× 3.7k 1.0× 4.4k 1.2× 4.5k 1.7× 381 14.0k
Terry L. Smith United States 65 7.7k 0.7× 1.5k 0.3× 4.2k 1.2× 2.8k 0.8× 2.6k 1.0× 154 16.0k
Ann D. Thor United States 68 9.7k 0.8× 3.4k 0.8× 5.8k 1.6× 8.3k 2.3× 2.4k 0.9× 209 18.3k
Christoph Zielinski Austria 69 10.1k 0.9× 2.0k 0.5× 2.6k 0.7× 5.0k 1.4× 5.7k 2.1× 499 20.8k
John A. Glaspy United States 75 10.9k 1.0× 2.0k 0.5× 1.8k 0.5× 5.1k 1.4× 2.3k 0.9× 338 21.4k
Joyce O’Shaughnessy United States 53 10.3k 0.9× 1.9k 0.4× 4.4k 1.2× 3.0k 0.8× 3.9k 1.4× 347 14.0k
Masahiro Nakano Japan 31 5.7k 0.5× 1.3k 0.3× 5.6k 1.5× 5.4k 1.5× 2.7k 1.0× 159 13.7k

Countries citing papers authored by Charles L. Vogel

Since Specialization
Citations

This map shows the geographic impact of Charles L. Vogel's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Charles L. Vogel with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Charles L. Vogel more than expected).

Fields of papers citing papers by Charles L. Vogel

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Charles L. Vogel. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Charles L. Vogel. The network helps show where Charles L. Vogel may publish in the future.

Co-authorship network of co-authors of Charles L. Vogel

This figure shows the co-authorship network connecting the top 25 collaborators of Charles L. Vogel. A scholar is included among the top collaborators of Charles L. Vogel based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Charles L. Vogel. Charles L. Vogel is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Kittaneh, Muaiad, Sunil Badve, Humberto Caldera, et al.. (2020). Case-Based Review and Clinical Guidance on the Use of Genomic Assays for Early-Stage Breast Cancer: Breast Cancer Therapy Expert Group (BCTEG). Clinical Breast Cancer. 20(3). 183–193. 12 indexed citations
2.
Ramdial, Jeremy, et al.. (2019). Vinorelbine plus Capecitabine (Vinocap): a retrospective analysis in heavily pretreated HER2 negative metastatic breast cancer patients. Breast Cancer Research and Treatment. 176(2). 253–260. 2 indexed citations
3.
Mahtani, Reshma, Sunil Badve, Humberto Caldera, et al.. (2019). A Roundtable Discussion of the Breast Cancer Therapy Expert Group (BCTEG): Clinical Developments and Practice Guidance on Human Epidermal Growth Factor Receptor 2 (HER2)-positive Breast Cancer. Clinical Breast Cancer. 20(3). e251–e260. 17 indexed citations
4.
5.
Abu‐Khalaf, Maysa, Ingrid A. Mayer, Andrew R. Allen, et al.. (2015). A phase 2, randomized, open-label study of lucitanib in patients with FGF aberrant metastatic breast cancer.. Journal of Clinical Oncology. 33. 2 indexed citations
6.
Kaufman, Peter A., Kenneth J. Bloom, Howard A. Burris, et al.. (2014). Assessing the discordance rate between local and central HER2 testing in women with locally determined HER2‐negative breast cancer. Cancer. 120(17). 2657–2664. 47 indexed citations
7.
Girish, Sandhya, Manish Gupta, Bei Wang, et al.. (2012). Clinical pharmacology of trastuzumab emtansine (T-DM1): an antibody–drug conjugate in development for the treatment of HER2-positive cancer. Cancer Chemotherapy and Pharmacology. 69(5). 1229–1240. 198 indexed citations
8.
Ahn, Eugene R. & Charles L. Vogel. (2011). Dual HER2-targeted approaches in HER2-positive breast cancer. Breast Cancer Research and Treatment. 131(2). 371–383. 44 indexed citations
9.
Hugh, Judith, John Hanson, Maggie C.U. Cheang, et al.. (2009). Breast Cancer Subtypes and Response to Docetaxel in Node-Positive Breast Cancer: Use of an Immunohistochemical Definition in the BCIRG 001 Trial. Journal of Clinical Oncology. 27(8). 1168–1176. 407 indexed citations
10.
Martín, Miguel, John R. Mackey, & Charles L. Vogel. (2007). Benefit from adjuvant taxanes and endocrine responsiveness in breast cancer. The Breast. 16. 127–131. 15 indexed citations
11.
Carlson, Robert W., Susan J. Moench, M. Elizabeth H. Hammond, et al.. (2006). HER2 Testing in Breast Cancer: NCCN Task Force Report and Recommendations. Journal of the National Comprehensive Cancer Network. 4(S3). S–1. 150 indexed citations
12.
13.
Vogel, Charles L., Melody Cobleigh, Debu Tripathy, et al.. (2002). Efficacy and Safety of Trastuzumab as a Single Agent in First-Line Treatment of HER2-Overexpressing Metastatic Breast Cancer. Journal of Clinical Oncology. 20(3). 719–726. 1508 indexed citations breakdown →
14.
Mass, R., Melody Cobleigh, Charles L. Vogel, & DJ Slamon. (2001). Estrogen receptor status in the Herceptin (trastuzumab) clinical trials: Incidence and relation to clinical benefit. Breast Cancer Research and Treatment. 69(3). 2 indexed citations
15.
Vogel, Charles L., Melody Cobleigh, Debu Tripathy, et al.. (2001). First-Line Herceptin<sup>®</sup> Monotherapy in Metastatic Breast Cancer. Oncology. 61(Suppl. 2). 37–42. 145 indexed citations
16.
Vogel, Charles L.. (1988). Adjuvant systemic therapy of primary breast cancer. Breast Disease. 1(2). 97–104. 24 indexed citations
17.
Cheresh, David A., et al.. (1982). Maximizing differences in the concanavalin A-induced blastogenic responses of lymphocytes from breast cancer patients and controls by the use of alpha-methyl-D-mannoside.. PubMed. 68(1). 68–9.
18.
Vogel, Charles L.. (1979). [Dental injuries during general anaesthesia and their forensic consequences (author's transl)].. Munich Personal RePEc Archive (Ludwig Maximilian University of Munich). 28(7). 347–9. 11 indexed citations
19.
Primack, Aron, Charles L. Vogel, & L. F. Barker. (1973). Immunological Studies in Ugandan Patients with Hepatocellular Carcinoma. BMJ. 1(5844). 16–19. 40 indexed citations
20.
Anthony, P. P., et al.. (1972). Hepatitis-associated Antigen and Antibody in Uganda: Correlation of Serological Testing with Histopathology. BMJ. 1(5797). 403–406. 33 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by M. Elizabeth Hammond Breakdown of academic impact, for papers by Michael J. Mihatsch Breakdown of academic impact, for papers by Rebecca Gelman Breakdown of academic impact, for papers by Sabino De Placido Breakdown of academic impact, for papers by Terry L. Smith Breakdown of academic impact, for papers by Ann D. Thor Breakdown of academic impact, for papers by Christoph Zielinski Breakdown of academic impact, for papers by John A. Glaspy Breakdown of academic impact, for papers by Joyce O’Shaughnessy Breakdown of academic impact, for papers by Masahiro Nakano
Rankless by CCL
2026